Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3DProSeed

Financiado

Cerrado

3DProSeed the first ready to use pre assembled hydrogel microtiter plate for...

3DProSeed the first ready to use pre assembled hydrogel microtiter plate for 3D cell culturess Capital investment in new pharmaceuticals to get from bench to clinical trial is estimated to be $1 billion per successful molecule, and only 10% of the compounds progress successfully through clinical development. Cell-based assa... ver más

30/04/2018

Ectica

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ECTICA TECHNOLOGIES AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-04-30

SMEInst-02-2016-2017: Accelerating the uptake of nanotech...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Ectica

50.00K€ | Lider

INTEC AIR

647.65K€ | Participante

Proyectos interesantes

DifMATRIX

Medical Technol...

Biotechnology

71K€ Cerrado

BOC

Medical Technol...

Biotechnology

2M€ Cerrado

ECM_INK

Medical Technol...

Biotechnology

2M€ Cerrado

ARON

Medical Technol...

Materials Scien...

71K€ Cerrado

OPTIMIsE

Medical Technol...

Materials Scien...

71K€ Cerrado

TechTissue

Medical Technol...

Materials Scien...

75K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 2 meses Fecha Inicio: 2018-02-08
Fecha Fin: 2018-04-30

Líder del proyecto

ECTICA TECHNOLOGIES AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Capital investment in new pharmaceuticals to get from bench to clinical trial is estimated to be $1 billion per successful molecule, and only 10% of the compounds progress successfully through clinical development. Cell-based assays screenings are the key tool used to assess the potential efficacy of a new compound in drug discovery, as it provides a simple, fast, and cost-effective approach to avoid large-scale and cost-intensive animal testing at early stages. Therefore, the development of in vitro cell-based systems that can more realistically mimic the in vivo cell behaviours is a raising market, with a CAGR2013-2018 of 12.4% growth rate and quantified in $21.6 billion by 2018. Drug research cell-based assays are mostly conducted with cell cultures on flat surface (2D), but they differ from human tissues significantly and can respond aberrantly to stimuli, resulting in missed discoveries and late-stage clinical failures of drugs in development. In contrast, 3D cell systems have a greater predictable power as they can better mimic the physiological environment in organs and tissues. Still, 2D cell culture systems offer advantages like the simplicity of handling and high data reproducibility that are not found in the current 3D cell systems. The last ones are very difficult to handle and not ready-to-use ones, giving poor consistency, data reproducibility and poor workflow integration. In response, we have developed 3DProSeed, the first ready-to-use solutions in the 3D cell culture market. Based on a patented novel process for manufacturing and encapsulating the cell growth matrix, known as hydrogel, inside 96-microtiter plates, we will be able to launch to the market the first ready-to-use, pre-assembled, hydrogel-based consumable products for pre-clinical screening development. As a result, 3DProSeed will reduce the operative cost up of R&D to 15%, will increase predictive efficacy of assays, impacting on our company with €15.22 M revenues after 5-years period.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores